Sandra Vassos has been named the new executive director of the AUA Foundation.
Sandra Vassos has been named the new executive director of the AUA Foundation.
Vassos served most recently as senior vice president and chief development officer at the American Liver Foundation. She has more than 17 years of experience in building development operations, integrating functions, and establishing long-term donor and institutional partnerships.
In her new capacity, the AUA Foundation said she will provide an immediate contribution as a persuasive and powerful spokesperson who will lead the organization to the next tier of excellence.
"The background and proven achievements that Sandra brings with her will help guide the Foundation towards achieving its goal to lead patient/public education, advocacy, and research efforts for urology," said AUA Executive Director Mike Sheppard, CPA, CAE.
Separately, AUA has announced that Alec Stone has joined the organization as director of government relations and advocacy, where he will be responsible for leading the formulation, coordination, and execution of AUA's national and state legislative advocacy efforts.
Stone was most recently executive director of Friends of the National Institute of Dental and Craniofacial Research, where he oversaw congressional, administration, and coalition-building efforts and created the Congressional Oral Health Caucus. He has 17-plus years of experience working in the political arena.
AUA, SUFU publish 2024 guideline for idiopathic overactive bladder
April 25th 2024“This brand new guideline offers options for all patients with OAB with a focus on shared decision-making between patients with OAB and clinicians, as well as a personalized, tailored approach to care,” said Cameron and Smith.
Enzalutamide granted approval in EU for nmHSPC
April 24th 2024The approval is supported by data from the phase 3 EMBARK trial, which demonstrated that enzalutamide with or without leuprolide prolonged metastasis-free survival compared with leuprolide alone in patients with high-risk biochemically recurrent nmHSPC.